MD Anderson Shows Enrollment on Genomically Matched Clinical Trial Improves Sarcoma Outcomes

Scientist using microscope with others besides him in the laboratory TrialsiteN

MD Anderson Cancer Center reports enrollment on genomically matched clinical trials improves Sarcoma outcomes.

MD Anderson Cancer Center participated in a clinical trial that revealed patients with various subtypes of pretreated, metastatic Sarcoma improved response rates and survival when treated on genomically matched phase 1 trials as was reported at ASCO.


Cancer that arises from transformed cells of connective tissue (mesenchymal) origin. Connective tissue is a broad term that includes bone, cartilage, fat, vascular, or hematopoietic tissues, and Sarcomas can arise in any of these types of tissues.

Consequently, there are many subtypes of Sarcoma, which are classified based on the specific tissue and type of cell from which the tumor originates. Sarcomas are primary connective tissue tumors, meaning they arise in connective tissue. This is in contract to secondary (or metastatic) connective tissue tumors, which occur when cancer from elsewhere in the body (such as the lungs, breast tissue or prostate) spreads to the connective tissue.

The Study

The investigators analyzed clinical and next-generation sequencing data from 406 patients (median age, 53 years; range, 11-84; 48% female)—including 321 with soft tissue Sarcomas and 85 with bone Sarcomas—treated on Phase 1 clinical trials between May 2006 and May 2019 at MD Anderson Cancer Center. Patients had a median of three (range 0-9) prior lines of therapy.

The Most Common Soft Tissue Subtypes Included:

  • Leiomyosarcoma 16%
  • Liposarcoma 13%
  • Gastrointestinal stromal tumors 11%
  • Synovial Sarcoma 3%

The Most Common Bone Sarcomas Include:

  • The osteosarcoma 8%
  • Chondrosarcoma 7%
  • Ewing Sarcoma 6%

250 of the patients underwent next-generation sequencing and 156 did not. 23% of the patients (n=93) received treatment on genomically matched trials.

The 313 patients enrolled in nongenomically matched trials received treatments such as immunotherapy, monoclonal antibodies, and antibody-drug conjugates.

Investigator Comment

Vivek Subbiah, MD, associate professor in the department of investigational cancer therapeutics and medical director of the Center for Targeted Therapy at the University of MD Anderson Cancer Center noted “Our main goals were to determine whether next-generation sequencing has affected drug development in Sarcoma, and how to optimize precision medicine for Sarcoma.